Benefits
Immune modulation and upper-respiratory support
Astragalus polysaccharides activate macrophages, NK cells, T-cells, and B-cells through multiple pattern recognition receptor pathways. An independent review that searched for placebo-controlled trials of oral Astragalus alone to prevent frequent respiratory infections in children found no qualifying randomized trials, so a preventive effect is not confirmed in controlled human studies; effects on vaccine response and NK cell activity rest largely on laboratory and animal data.
Telomerase-activating activity (cycloastragenol)
In cell studies, cycloastragenol and astragaloside IV activate telomerase (hTERT), the enzyme that extends telomeres. In a 12-month open-label program pairing TA-65® with a multi-ingredient supplement pack, the share of short telomeres fell in a 13-person subset (mean telomere length did not increase) and some immune-aging markers improved. With no placebo group, results cannot be credited to TA-65 alone, let alone whole astragalus.
Kidney and cardiovascular tissue support
Astragalus polysaccharides demonstrate protective effects in cardiac and renal tissue, supporting heart and kidney tissue in preclinical models and some lower-quality human studies. An independent review of astragalus in chronic kidney disease found possible benefit but rated overall study quality as low and drew no definitive conclusions. Chinese clinical trials, mostly lower quality, have also explored cardiovascular adjunct uses.
Blood sugar regulation
In laboratory and animal studies, APS has been reported to improve insulin sensitivity, lower fasting blood glucose, and protect pancreatic beta cells from oxidative damage. Most of this evidence comes from animal models; human trials are limited, small, and generally lower quality, so blood-sugar benefits in people are not well established.
Traditional adaptogenic tonic use
Astragalus has traditionally been used as a tonic and anti-aging herb in TCM. Direct human evidence for cortisol reduction or increased energy is limited and preliminary. The combination of immune modulation, telomerase activation, antioxidant activity, and metabolic benefits makes astragalus a popular longevity-oriented botanical, though most of these effects rest on traditional use and preclinical data rather than strong human outcomes.
Mechanism of action
TLR-4 and Dectin-1 immune receptor activation
Astragalus polysaccharides bind TLR-4 and Dectin-1 pattern recognition receptors on macrophages and dendritic cells, activating NF-κB-dependent innate immune responses including cytokine production, NK cell activation, and dendritic cell maturation. In laboratory and animal studies this priming has been linked to infection defense and vaccine responses; human evidence is limited and of low quality.
Telomerase reverse transcriptase (hTERT) activation
In cell studies, astragaloside IV and cycloastragenol increase telomerase activity and appear to act through Src/MEK/ERK signaling. Whether this meaningfully slows immune-cell aging in people is not established.
PI3K/Akt/mTOR pathway modulation for cellular protection
Astragalosides modulate the PI3K/Akt survival pathway in cardiac, renal, and immune cells, reducing apoptosis in stressed cells, improving mitochondrial membrane potential, and supporting cellular energy metabolism under hypoxic or inflammatory conditions.
Clinical trials
Single-arm, open-label observational analysis of a commercial program (PattonProtocol-1): TA-65® (a purified compound isolated from Astragalus root, 10-50 mg/day) plus a dietary supplement pack and physician counseling, in 114 adults (mean age 63 ± 12 years) over 12 months. Outcomes: telomere length distribution (13-person subset), CD8+CD28- senescent T cells, results by cytomegalovirus status. (Harley, Liu et al. 2011, Rejuvenation Res)
114 adults at baseline (mean age 63 ± 12 years, 72% male); 37 evaluable at 12 months for most tests; telomere distribution measured in 13. 12-month observational.
In a 13-person subset, the share of short (<4 kbp) leukocyte telomeres fell versus baseline; mean telomere length did not increase. The percentage of senescent CD8+CD28- T cells declined, mostly in CMV-seropositive subjects. Limitations: open-label, no placebo; TA-65 was taken with a supplement pack and physician counseling, so effects cannot be attributed to TA-65 alone; the authors planned controlled trials to test TA-65-specific effects.
Cochrane systematic review searching English and Chinese databases for randomized placebo-controlled trials of oral Astragalus alone to prevent frequent acute respiratory tract infections in children up to age 14. (Su G, et al. 2016, Cochrane Database Syst Rev CD011958)
Children up to 14 years; screened 6080 records, no qualifying randomized trials met inclusion.
After screening 6080 records, no placebo-controlled randomized trials of oral Astragalus as a sole agent met the inclusion criteria. The authors concluded there is insufficient evidence to assess whether oral Astragalus prevents frequent respiratory infections in children. Traditional immune use and laboratory immune-modulating effects provide mechanistic rationale, but a preventive benefit is not confirmed by controlled human trials.